GSK-345931A | CAS#869499-38-7 | 869534-13-4 | EP Receptor Antagonist

MedKoo Cat#: 525222 | Name: GSK-345931A

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK-345931A is an EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain. GSK-345931A shows measurable CNS penetration in the mouse and rat and potent analgesic efficacy in acute and sub-chronic models of inflammatory pain.

Chemical Structure

GSK-345931A

CAS#869499-38-7 (Salt)

Theoretical Analysis

MedKoo Cat#: 525222

Name: GSK-345931A

CAS#: 869499-38-7 (Salt)

Chemical Formula: C22H19ClNNaO3

Exact Mass:

Molecular Weight: 403.83

Elemental Analysis: C, 65.43; H, 4.74; Cl, 8.78; N, 3.47; Na, 5.69; O, 11.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

869499-38-7 (Salt) 869534-13-4(Free base)

Synonym

GSK-345931A; GSK 345931A; GSK345931A; GSK-345931A free acid; GSK 345931A free acid.

IUPAC/Chemical Name

2-Pyridinecarboxylic acid, 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)-, sodium salt

InChi Key

HCPQFFJXXAUWBN-UHFFFAOYSA-M

InChi Code

InChI=1S/C22H20ClNO3.Na/c1-14(2)13-27-21-11-10-15(23)12-18(21)16-6-3-4-7-17(16)19-8-5-9-20(24-19)22(25)26;/h3-12,14H,13H2,1-2H3,(H,25,26);/q;+1/p-1

SMILES Code

O=C(C1=NC(C2=CC=CC=C2C3=CC(Cl)=CC=C3OCC(C)C)=CC=C1)[O-].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 403.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jiang KL, Ma PP, Yang XQ, Zhong L, Wang H, Zhu XY, Liu BZ. Neutrophil elastase and its therapeutic effect on leukemia cells. Mol Med Rep. 2015 Sep;12(3):4165-72. doi: 10.3892/mmr.2015.3946. Epub 2015 Jun 17. PubMed PMID: 26081156; PubMed Central PMCID: PMC4526057. 2: Ma PP, Zhu D, Liu BZ, Zhong L, Zhu XY, Wang H, Zhang X, Gao YM, Hu XX. [Neutrophil elastase inhibitor on proliferation and apoptosis of U937 cells]. Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):507-11. doi: 10.3760/cma.j.issn.0253-2727.2013.06.011. Chinese. PubMed PMID: 23827109. 3: Mansuy-Aubert V, Zhou QL, Xie X, Gong Z, Huang JY, Khan AR, Aubert G, Candelaria K, Thomas S, Shin DJ, Booth S, Baig SM, Bilal A, Hwang D, Zhang H, Lovell-Badge R, Smith SR, Awan FR, Jiang ZY. Imbalance between neutrophil elastase and its inhibitor α1-antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure. Cell Metab. 2013 Apr 2;17(4):534-48. doi: 10.1016/j.cmet.2013.03.005. PubMed PMID: 23562077; PubMed Central PMCID: PMC3646573. 4: Benedek B, Kopp B, Melzig MF. Achillea millefolium L. s.l. -- is the anti-inflammatory activity mediated by protease inhibition? J Ethnopharmacol. 2007 Sep 5;113(2):312-7. Epub 2007 Jul 3. PubMed PMID: 17689902. 5: Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. Review. PubMed PMID: 12084007. 6: Cooke JW, Berry MB, Caine DM, Cardwell KS, Cook JS, Hodgson A. A novel and selective approach to enantiomerically pure bicyclic-trans-lactams via a titanium enolate of a thiopyridyl ester. J Org Chem. 2001 Jan 12;66(1):334-6. PubMed PMID: 11429923. 7: Macdonald SJ, Dowle MD, Harrison LA, Shah P, Johnson MR, Inglis GG, Clarke GD, Smith RA, Humphreys D, Molloy CR, Amour A, Dixon M, Murkitt G, Godward RE, Padfield T, Skarzynski T, Singh OM, Kumar KA, Fleetwood G, Hodgson ST, Hardy GW, Finch H. The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate. Bioorg Med Chem Lett. 2001 Apr 9;11(7):895-8. PubMed PMID: 11294386. 8: Dear GJ, Ayrton J, Plumb R, Fraser IJ. The rapid identification of drug metabolites using capillary liquid chromatography coupled to an ion trap mass spectrometer. Rapid Commun Mass Spectrom. 1999;13(5):456-63. PubMed PMID: 10209877.